SCYX (SCYNEXIS) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCYX SCYNEXIS Inc SCYX
40 GF Score
Price $5.09
GF Value $17.37
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SCYNEXIS Short-term investments?

Short-term investments only applies to insurance companies.

SCYX
40GF Score
SCYNEXIS Inc SCYX
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SCYNEXIS (SCYX) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of $5.09 is trading 70.7% below its estimated GF Value™ of $17.37. GuruFocus considers SCYNEXIS to be Possible Value Trap.

Key valuation signals for SCYX:

  • Short-term investments:
  • GF Value™: $17.37 vs. price of $5.09 (70.7% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the SCYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SCYNEXIS Business Description

Other Exchanges 0L49:UK135:Germany
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
40GF Score

Get the complete analysis for SCYX

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.09
Price
$17.37
GF Value